A Phase 2a Study to Assess Safety, Daily Symptoms, Pharmacokinetics (PK), and Biomarkers of YPL-001 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Inclusion Criteria:

- Adult males and/or females, 40 to 80 years of age (inclusive).

- History of COPD for at least 12 months prior to screening.

- Diagnosed with COPD as defined by the American Thoracic Society (ATS)/European
Respiratory Society (ERS) guidelines with symptoms compatible with COPD for at least
12 months prior to screening.

- Classified as moderate to severe COPD based on the current severity classification
GOLD Stage 2-3 disease in terms of post-bronchodilator spirometry at screening

- etc.

Exclusion Criteria:

- History of life-threatening COPD including respiratory arrest, intensive care unit
admission and/or requiring intubation.

- History of more than 2 hospitalizations for COPD within 12 months prior to screening.

- Presentation of an acute exacerbation of COPD that will be associated with increase
sputum volume or change in sputum color within 4 weeks before Day 1 of the Run-in
Period.

- Evidence of pulmonary heart disease, or clinically significant pulmonary
hypertension.

- etc.